Anika Therapeutics | ANIK - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Abbott USD 4.27B 669M 2026-09
Agenus USD 6.21M 4.34M 2026-03
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Halozyme Therapeutics USD 57M 10.71M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 253.03M 5.56M 2026-09
Integra LifeSciences USD 161.02M 5.2M 2026-09
Intrexon USD 10.31M 41K 2024-06
J&J USD 6.25B 168M 2026-09
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 72.62M 43.49M 2026-09
MacroGenics USD 7.9M 1.81M 2026-06
Merit Medical Systems USD 129.23M 18.76M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.31B 325M 2026-09
Smith & Nephew USD 1.45B 29M 2026-06
Stryker USD 2.12B 32M 2026-06
Veracyte USD 57.95M 2.25M 2026-09
Xencor USD 71.93M 5.61M 2026-09
Zimmer Biomet Holdings USD 855M 56.6M 2026-09